Neurotoxicity following atezolizumab in a patient with tolerated rechallenge

Therapie. 2024 May-Jun;79(3):393-396. doi: 10.1016/j.therap.2023.03.007. Epub 2023 Mar 17.

Authors

Yasmine Salem Mahjoubi¹, Imen Aouinti², Ons Charfi², Ahmed Zaiem², Widd Kaabi², Ghozlane Lakhoua², Riadh Daghfous², Sihem El Aidli²

Affiliations

¹ National Center Chalbi Belkahia of Pharmacovigilance, 9, avenue du Dr Zouhaier Essafi, 1006 Tunis, Tunisia. Electronic address: m.yasmin7951@gmail.com.
² National Center Chalbi Belkahia of Pharmacovigilance, 9, avenue du Dr Zouhaier Essafi, 1006 Tunis, Tunisia; University of Tunis El Manar, Faculty of Medicine, Research unit: UR17ES12, 1006 Tunis, Tunisia.

PMID: 37730448
DOI: 10.1016/j.therap.2023.03.007

No abstract available

Keywords: Adverse drug reaction; Central nervous system; Immune checkpoint inhibitor; Seizures; Tecentriq; anti-PDL1.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / adverse effects
Female
Humans
Lung Neoplasms / drug therapy
Male
Middle Aged
Neurotoxicity Syndromes* / etiology

Substances

Antibodies, Monoclonal, Humanized
atezolizumab